Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Infectious disease · Phase II

Infectious disease programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs 365

Quick answer

Infectious disease Phase II programs: NovaPharmaNews indexes 365 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Pipeline programs

Page 6 of 8

  1. REGN7544

    Regeneron UK Limited

    Sepsis-Induced Hypotension

    phase 2 small molecule completed

    1 trial

  2. REGN7544, REGN7544 Matching Placebo

    Lacuna Pharma Pty Ltd

    Sepsis-Induced Hypotension

    phase 2 small molecule active

    1 trial

  3. RILPIVIRINE , JNJ-16150108

    Xian-Janssen Pharmaceutical

    HIV-1 Infection

    phase 2 small molecule active

    1 trial

  4. RO5024048

    Hoffmann-La Roche

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  5. Rapamune 1 mg/mL oral solution

    Tour Hekla

    Lingual microcystic lymphatic malformations (LMLMs) are rare congenital vascular malformations, presenting as clusters of cysts filled with lymph fluid or blood. They are responsible for a heavy burden even with small well-limited lesions because of oozing, bleeding, infections, or even speech, chewing or breathing impairment. Pain and aesthetic prejudice are also frequently reported

    phase 2 small molecule active

    1 trial

  6. Recombinant COVID-19 Vaccine (CHO cell)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19 Pneumonia

    phase 2 mab active

    1 trial

  7. Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19 Pneumonia

    phase 2 mab active

    1 trial

  8. Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 mab active

    1 trial

  9. Recombivax

    BRIGHT MINDS BIOSCIENCES INC.

    Hepatitis B

    phase 2 mab completed

    1 trial

  10. Rencofilstat

    Hepion Pharmaceuticals

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  11. Resmetirom

    Madrigal Pharmaceuticals EU Limited

    MASH - Metabolic Dysfunction-Associated Steatohepatitis

    phase 2 small molecule active

    1 trial

  12. Ribavirin

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 2 small molecule completed

    1 trial

  13. Ridinilazole

    Summit Therapeutics

    Clostridium Difficile Infection

    phase 2 small molecule completed

    1 trial

  14. Rifaximin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Small Intestine Bacterial Overgrowth

    phase 2 small molecule active

    1 trial

  15. Rilpivirine

    Janssen Cilag International NV

    HIV-1

    phase 2 small molecule completed

    1 trial

  16. Rotarix™

    GlaxoSmithKline

    Infections, Rotavirus

    phase 2 mab completed

    1 trial

  17. S-337395

    Shionogi B.V.

    Respiratory Syncytial Virus Infections

    phase 2 small molecule active

    1 trial

  18. SA55 Injection

    Sinovac Research and Development Co.,

    Infection of Upper Respiratory Tract Caused by 2019-nCoV

    phase 2 small molecule active

    1 trial

  19. SB-728-T

    SANGAMO THERAPEUTICS, INC

    HIV

    phase 2 gene therapy completed

    2 trials

  20. SB-728mR-T

    SANGAMO THERAPEUTICS, INC

    Human Immunodeficiency Virus (HIV)

    phase 2 gene therapy completed

    1 trial

  21. SDZ MSL-109

    Ultragenyx UK Limited

    Cytomegalovirus Infections

    phase 2 small molecule completed

    1 trial

  22. SHP626

    Mirum Pharmaceuticals International B.V.

    Non-Alcoholic Steatohepatitis

    phase 2 small molecule completed

    3 trials

  23. SMT19969

    Summit Therapeutics

    Clostridium Difficile Infection

    phase 2 small molecule completed

    1 trial

  24. SOF

    Gilead Sciences Ireland UC

    HCV Infection

    phase 2 small molecule completed

    1 trial

  25. SOF

    Gilead Sciences Ireland UC

    Hepatitis C Virus Infection

    phase 2 small molecule completed

    1 trial

  26. Sargramostim

    United Therapeutics Europe Ltd

    COVID-19

    phase 2 small molecule completed

    1 trial

  27. Sargramostim

    Hospital Authority, Hong Kong

    COVID

    phase 2 small molecule completed

    1 trial

  28. Sargramostim

    United Therapeutics Europe Ltd

    Covid19

    phase 2 small molecule completed

    1 trial

  29. Selinexor

    Karyopharm Therapeutics Inc

    Coronavirus Infection

    phase 2 small molecule completed

    2 trials

  30. Sinovac Low-dosage PCV24

    Sinovac Research and Development Co.,

    Pneumococcal Infectious Disease

    phase 2 mab completed

    1 trial

  31. Sinovac PCV24

    Sinovac Research and Development Co.,

    Pneumococcal Infectious Disease

    phase 2 mab active

    2 trials

  32. Sofosbuvir

    BRIGHT MINDS BIOSCIENCES INC.

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  33. Sotrovimab

    Vir Biotechnology

    COVID-19

    phase 2 mab terminated

    1 trial

  34. Sotrovimab (Gen1)

    Vir Biotechnology

    Covid19

    phase 2 mab completed

    1 trial

  35. Standard of care and PrEP Choice at Enrollment

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other active

    1 trial

  36. Subcutaneous injection of TAK-850

    Takeda

    Influenza Infection

    phase 2 small molecule completed

    1 trial

  37. TAK-019

    Takeda

    Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

    phase 2 mab completed

    1 trial

  38. TAK-850

    Takeda

    Influenza Infection

    phase 2 mab completed

    1 trial

  39. TAK-850 0.5 mL injection

    Takeda

    Influenza Infection

    phase 2 small molecule completed

    1 trial

  40. TAK-919

    Takeda

    Coronavirus Disease (COVID-19)

    phase 2 mab completed

    1 trial

  41. TD-0903

    Theravance Biopharma Ireland Umited

    Acute Lung Injury (ALI) Associated With COVID-19

    phase 2 small molecule completed

    2 trials

  42. TD-1792

    Theravance Biopharma Ireland Umited

    Staphylococcal Skin Infection

    phase 2 small molecule completed

    1 trial

  43. TENOFOVIR ALAFENAMIDE for Hepatitis B and Hepatitis D Viral Co-infection

    Janssen-Cilag International N.V.

    Hepatitis B and Hepatitis D Viral Co-infection

    phase 2 small molecule active

    1 trial

  44. TEV-45478

    Teva Pharma GmbH

    Nonalcoholic Steatohepatitis

    phase 2 small molecule terminated

    1 trial

  45. TG-873870 (Nemonoxacin)

    Biotech Pharmaceutical Co.,

    Diabetic Foot Infections

    phase 2 small molecule completed

    1 trial

  46. THALASSA 2.0

    MEDA Pharma GmbH & Co. KG

    post-COVID-19 Condition (PCC)

    phase 2 small molecule active

    1 trial

  47. TMC435

    Elan Pharma International

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  48. TNX-102 SL

    Tonix Pharmaceuticals Holding

    Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many infectious disease Phase II programs exist?

365 programs match both the therapeutic area and stage filters in our published index.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.